| Teva Pharmaceuticals USA |
00093526398 |
SOLIFENACIN SUCCINATE TABLETS 5MG 90 |
2019-04-22 |
999.2400 |
None |
1 |
80000 |
None |
None |
None |
None |
None |
None |
Estimated patient volume of approximately 80,000 patients per month for 5mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093526498 |
SOLIFENACIN SUCCINATE TABLETS 10MG 90 |
2019-04-22 |
999.2400 |
None |
1 |
86000 |
None |
None |
None |
None |
None |
None |
Estimated patient volume of approximately 86,000 patients per month for 10mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093766356 |
ERLOTINIB HCL TABLETS EQ 100MG 30 |
2019-05-09 |
6455.8200 |
None |
1 |
660 |
None |
None |
None |
None |
None |
None |
Estimated patient volume of approximately 660 patients per month for 100mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093765256 |
VARDENAFIL HCL TABLETS 2.5MG 30 |
2019-01-03 |
704.5900 |
None |
1 |
101361 |
None |
None |
None |
None |
None |
Acquisition date and acquisition price not applicable; Teva developed this product. |
Projected count of 101,361 patients in 2018, based on IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00093765356 |
VARDENAFIL HCL TABLETS 5MG 30 |
2019-01-03 |
704.5900 |
None |
1 |
101361 |
None |
None |
None |
None |
None |
Acquisition date and acquisition price not applicable; Teva developed this product. |
Projected count of 101,361 patients in 2018, based on IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00093765456 |
VARDENAFIL HCL TABLETS 10MG 30 |
2019-01-03 |
704.5900 |
None |
1 |
101361 |
None |
None |
None |
None |
None |
Acquisition date and acquisition price not applicable; Teva developed this product. |
Projected count of 101,361 patients in 2018, based on IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00093765556 |
VARDENAFIL HCL TABLETS 20MG 30 |
2019-01-03 |
704.5900 |
None |
1 |
101361 |
None |
None |
None |
None |
None |
Acquisition date and acquisition price not applicable; Teva developed this product. |
Projected count of 101,361 patients in 2018, based on IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00591385101 |
VIGABATRIN 500MG TABLETS 100 |
2019-02-06 |
11487.3000 |
None |
1 |
5000 |
None |
1 |
None |
None |
None |
Acquisition date and acquisition price not applicable; Teva developed this product. |
Estimated count of approximately 5,000 patients per year. |
None |
| Teva Pharmaceuticals USA |
45963045430 |
DEFERASIROX 125MG TABLETS 30 |
2019-03-22 |
750.9900 |
None |
1 |
900 |
None |
None |
None |
None |
None |
None |
Projected count of approximately 900 patients annually, based on IQVIA data as of February 2019. Also, acquisition date and acquisition price not applicable; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
45963045530 |
DEFERASIROX 250MG TABLETS 30 |
2019-03-22 |
1501.9500 |
None |
1 |
900 |
None |
None |
None |
None |
None |
None |
Projected count of approximately 900 patients annually, based on IQVIA data as of February 2019. Also, acquisition date and acquisition price not applicable; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
45963045630 |
DEFERASIROX 500MG TABLETS 30 |
2019-03-22 |
3003.8400 |
None |
1 |
900 |
None |
None |
None |
None |
None |
None |
Projected count of approximately 900 patients annually, based on IQVIA data as of February 2019. Also, acquisition date and acquisition price not applicable; Teva developed this product. |
None |
| Teva Pharmaceuticals USA |
00591240530 |
AMBRISENTAN 5MG FC TABLETS 30 |
2019-04-30 |
2766.8100 |
None |
1 |
650 |
None |
1 |
None |
None |
None |
None |
Estimated patient volume of approximately 650 patients per month for 5mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591240630 |
AMBRISENTAN 10MG FC TABLETS 30 |
2019-04-30 |
2766.8100 |
None |
1 |
1600 |
None |
1 |
None |
None |
None |
None |
Estimated patient volume of approximately 1,600 patients per month for 10mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093766456 |
ERLOTINIB HCL TABLETS EQ 150MG 30 |
2019-05-09 |
7302.0100 |
None |
1 |
1120 |
None |
None |
None |
None |
None |
None |
Estimated patient volume of approximately 1,120 patients per month for 150mg dosage, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
45963041850 |
RANOLAZINE 500MG ER TABLETS 500 |
2019-05-28 |
711.2500 |
None |
1 |
145000 |
None |
None |
None |
None |
None |
None |
Approximately 145,000 total prescriptions per month, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
45963041950 |
RANOLAZINE 1000MG ER TABLETS 500 |
2019-05-28 |
1167.7500 |
None |
1 |
145000 |
None |
None |
None |
None |
None |
None |
Approximately 145,000 total prescriptions per month, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591251160 |
BOSENTAN 62.5MG FC TABLETS 60 |
2019-06-20 |
1326.0000 |
None |
1 |
375 |
None |
1 |
None |
None |
None |
None |
Average of approximately 375 total prescriptions per month (both dosages), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591251260 |
BOSENTAN 125MG FC TABLETS 60 |
2019-06-20 |
1326.0000 |
None |
1 |
375 |
None |
1 |
None |
None |
None |
None |
Average of approximately 375 total prescriptions per month (both dosages), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591417101 |
PENCILLAMINE 250MG CAPSULES 100 |
2019-06-24 |
22626.9900 |
None |
1 |
310 |
None |
1 |
None |
None |
None |
None |
Average of approximately 310 prescriptions per month, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093306634 |
ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 1 |
2019-07-15 |
5083.2600 |
None |
1 |
720 |
None |
None |
None |
None |
None |
None |
Average of approximately 720 total prescriptions per month (both pack sizes), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093306693 |
ICATIBANT ACETATE 10MG/ML PFS SOL 3ML 3 |
2019-07-15 |
15249.7800 |
None |
1 |
720 |
None |
None |
None |
None |
None |
None |
Average of approximately 720 total prescriptions per month (both pack sizes), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591455022 |
DOXYCYCLINE HYCLATE DR TABLET 50MG 120 |
2019-08-14 |
1134.6000 |
None |
1 |
270 |
None |
None |
None |
None |
None |
None |
Average of approximately 270 total prescriptions per month (both dosages), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591457560 |
DOXYCYCLINE HYCLATE DR TABLET 200MG 60 |
2019-08-14 |
2100.5100 |
None |
1 |
270 |
None |
None |
None |
None |
None |
None |
Average of approximately 270 total prescriptions per month (both dosages), based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. Note that although Teva's WAC on NDC 00591457560 was $2,100.51 at launch, Teva subsequently lowered the price, one week later (on August 21, 2019), to $1,500.37. See supporting documents: (1) Teva's original communication to customers and the compendia, sent on Aug. 14, announcing WAC on NDC 00591457560 at $2,100.51, and (2) Teva's follow-on communication to customers and compendia, sent on Aug. 21, noting an updated WAC on NDC 00591457560 of $1,500.37 (backdated to August 14). |
https://oshpd.ca.gov/ml/v1/resources/document?rs:path=/Data-And-Reports/Documents/Topics/Cost-Transparency/Rx/Q3-New-Drug-Public-Release-Supporting-Documents/Teva/2019-08-14-Doxy-Hyclate-DR-New-Product-Notification.pdf |
| Teva Pharmaceuticals USA |
00591501902 |
FULVESTRANT INJ 250MG/50ML INJ PFS SOL |
2019-08-22 |
1675.3500 |
None |
1 |
345 |
None |
None |
None |
None |
None |
None |
Average of approximately 345 prescriptions per month, based on IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00093363020 |
ACYCLOVIR CREAM 5% 5GM |
2019-08-29 |
729.4700 |
None |
1 |
8400 |
None |
None |
2016-08-02 |
-1.0000 |
None |
This product (the "Product") is an authorized generic version of Zovirax® Cream 5%. Watson Laboratories, Inc. (“Watson”) had an option to sell the Product, and on August 2, 2016, Teva acquired that option – which Teva would later exercise – along with Watson itself, as part of a broader deal involving other assets. The option’s acquisition price was incorporated into that broader deal’s overall purchase price and, thus, there was no one particular price that Teva paid to acquire the option. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the option in particular. |
Average of approximately 8,400 prescriptions per month, based on IQVIA data. |
None |
| Teva Pharmaceuticals USA |
00703066601 |
TREPROSTINIL SODIUM INJ 1MG/ML 20ML 1 |
2019-09-30 |
1209.6500 |
None |
1 |
550 |
None |
None |
None |
None |
None |
None |
Average of approximately 550 prescriptions per month (all dosages), based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00703067601 |
TREPROSTINIL SODIUM INJ 2.5MG/ML 20ML 1 |
2019-09-30 |
3024.1400 |
None |
1 |
550 |
None |
None |
None |
None |
None |
None |
Average of approximately 550 prescriptions per month (all dosages), based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00703068601 |
TREPROSTINIL SODIUM INJ 5MG/ML 20ML 1 |
2019-09-30 |
6048.2700 |
None |
1 |
550 |
None |
None |
None |
None |
None |
None |
Average of approximately 550 prescriptions per month (all dosages), based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00703069601 |
TREPROSTINIL SODIUM INJ 10MG/ML 20ML 1 |
2019-09-30 |
12096.5400 |
None |
1 |
550 |
None |
None |
None |
None |
None |
None |
Average of approximately 550 prescriptions per month (all dosages), based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
63459010310 |
TRUXIMA® (rituximab-abbs) 100 MG / 10 ML |
2019-11-11 |
845.5500 |
The Wholesale Acquisition Cost (WAC or “list price”) for TRUXIMA will be 10 percent lower than the reference product. TRUXIMA is being made available through primary wholesalers at a WAC of $845.55 for 100mg vial and $4227.75 for 500mg vial. Actual costs to individual patients and providers for TRUXIMA are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program. |
None |
2415 |
None |
None |
2016-10-04 |
1.0000 |
None |
Teva acquired rights on October 4, 2016 from Celltrion to commercialize TRUXIMA and another biosimilar product for $160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the TRUXIMA rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights. We were, nonetheless, required to enter a non-zero value in the "Acquisition Cost" field, and so we entered "1.00." |
None |
None |
| Teva Pharmaceuticals USA |
63459010450 |
TRUXIMA® (rituximab-abbs) 500 MG / 50 ML |
2019-11-11 |
4227.7500 |
The Wholesale Acquisition Cost (WAC or “list price”) for TRUXIMA will be 10 percent lower than the reference product. TRUXIMA is being made available through primary wholesalers at a WAC of $845.55 for 100mg vial and $4227.75 for 500mg vial. Actual costs to individual patients and providers for TRUXIMA are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program. |
None |
1469 |
None |
None |
2016-10-04 |
1.0000 |
None |
Teva acquired rights on October 4, 2016 from Celltrion to commercialize TRUXIMA and another biosimilar product for $160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the TRUXIMA rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights. We were, nonetheless, required to enter a non-zero value in the "Acquisition Cost" field, and so we entered "1.00." |
None |
None |
| Teva Pharmaceuticals USA |
00093351556 |
DEFERASIROX TABLETS 360MG 30 |
2019-11-25 |
2021.8100 |
None |
1 |
1950 |
None |
None |
None |
None |
None |
None |
Average of approximately 1,950 prescriptions per month, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Teva Pharmaceuticals USA |
00591385330 |
DEFERASIROX 180MG TABLETS 30 |
2019-12-17 |
2189.0700 |
None |
1 |
590 |
None |
None |
None |
None |
None |
None |
Average of approximately 590 prescriptions per month, based on historic IQVIA data. Acquisition questions not applicable (and acquisition fields therefore left blank); Teva developed the product. |
None |
| Titan Pharmaceuticals, Inc. |
52440010014 |
Probuphine Implant |
2019-03-01 |
4950.0000 |
None |
1 |
800 |
None |
None |
None |
None |
1 |
Product was marketed previously under the Braeburn labeler code, but Braeburn had a contract to market this product for Titan. Titan then took this back and started marketing the product again under their labeler code. The first shipment was available to consumers on 3/1/2019 for the Titan labeler code. |
None |
None |
| Theratechnologies Inc. |
62064024130 |
EGRIFTA SV (tesamorelin for injection) - sterile lyophilized powder 2mg/vial |
2019-11-25 |
5300.0000 |
Parity pricing to original Egrifta. Print Ad In-office detailing On-line advertising |
None |
108 |
None |
None |
None |
None |
None |
None |
Estimated volume of patients in CA is 108 |
None |
| TWi Pharmaceuticals USA, Inc. |
24979003504 |
Cyclobenzaprine Hydrochloride ER Capsule 15mg-60’s |
2019-03-01 |
900.0000 |
None |
1 |
3534 |
None |
None |
None |
None |
1 |
None |
Estimated number of patient is actually estimated number of bottles. We currently do not have an estimated number of patients that will be taking this product. |
None |
| TWi Pharmaceuticals USA, Inc. |
24979003604 |
Cyclobenzaprine HCl ER Oral Capsule Extended Release 24 Hour 30 MG |
2019-03-01 |
900.0000 |
None |
1 |
1485 |
None |
None |
None |
None |
1 |
None |
Estimated number of patients is actually estimated number of bottles. TWI does not currently have an estimated number of patients that will be taking this product on an annual basis. |
None |